Title: An extract of hops (*Humulus lupulus* L.) modulates gut peptide hormone secretion and reduces energy intake in healthy weight men: a randomised, cross-over clinical trial

Author Names: Edward G Walker¹, Kim R Lo¹, Malcolm C Pahl¹, Hyun Sang Shin^{3,4}, Claudia Lang¹, Mark W Wohlers¹, Sally D Poppitt³, Kevin H Sutton², John R Ingram^{1*}

Author Affiliations: ¹The New Zealand Institute for Plant and Food Research Limited, Auckland and ²Lincoln, New Zealand. ³Human Nutrition Unit; School of Biological Sciences, University of Auckland, Auckland, New Zealand. ⁴Current address: Checkmate Therapeutics Inc., Seoul, Korea.

Corresponding author: John Ingram, The New Zealand Institute for Plant and Food Research, Private Bag 92169, Auckland Mail Centre, Auckland 1142, New Zealand. Tel.: +64 9 9257119. Email: john.ingram@plantandfood.co.nz.

Sources of support: Supported by the New Zealand Ministry of Business, Innovation and Employment (MBIE) (Programme # C11X104 – Lifestyle Foods for Appetite Control)

Short running head: Hops extract reduces energy intake

Abbreviations list:

Area under the curve (AUC); bitter taste receptor (T2R); carbon dioxide (CO₂); cholecystokinin (CCK); energy intake (EI); enteroendocrine cell (EEC); gastrointestinal (GI); glucagon like peptide-1 (GLP-1); glucose-dependent insulinotropic polypeptide (GIP); glycated hemoglobin (HbA1c); human bitter taste receptor (hT2R); least significant difference (LSD); pancreatic polypeptide (PP); peptide YY (PYY); profile of mood states (POMS); visual analogue scale (VAS).

Clinical Trial Registry: ACTRN12614000434695 www.anzctr.org.au

Data described in the manuscript, code book, and analytic code will be made available upon request pending application and approval.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

- 2 **Background:** Gastrointestinal enteroendocrine cells express a range of chemosensory
- 3 receptors involved in detecting the chemical composition of food during digestion. These
- 4 receptors, including bitter taste receptors (T2Rs), may play an important role in regulating gut
- 5 function and appetite.
- 6 **Objective:** To establish the ability of Amarasate[®], a bitter supercritical CO₂ extract of hops
- 7 (Humulus lupulus L.) to modify acute energy intake, appetite and hormonal responses and
- 8 establish a site of action.
- 9 **Design:** Nineteen healthy-weight (BMI = $23.5 \pm 0.3 \text{ kg/m}^2$) male volunteers completed a
- randomised three-treatment, double blind, cross-over study with a 1 week washout between
- treatments. Overnight-fasted participants were cannulated and provided with a standardised 2
- MJ breakfast meal at 0900h. Treatments comprised a vehicle control (Placebo) or 500 mg of
- hops extract administered in either delayed release capsules (Duodenal) at 1100 h or quick
- release capsules (Gastric) at 1130 h. *Ad libitum* energy intake was recorded at an outcome
- meal (1200 h) and afternoon snack (1400 h), with blood samples taken and subjective ratings
- of appetite, gastrointestinal discomfort, vitality, meal palatability and mood assessed
- 17 throughout the day.
- 18 **Results:** Compared with placebo, both gastric and duodenal treatments significantly reduced
- 19 (p < 0.05) total *ad libitum* energy intake by 911 \pm 308 kJ and 944 \pm 309 kJ, respectively. Both
- 20 gastric and duodenal treatments significantly increased (p < 0.05) pre-meal ghrelin and post-
- 21 prandial CCK, GLP-1 and PYY responses while reducing postprandial insulin, GIP and PP
- secretion with no significant impact on glycemia. In addition, gastric and duodenal
- treatments produced small but significant (p < 0.05) changes in vitality and gastrointestinal
- 24 discomfort (e.g. nausea, bloating, abdominal discomfort) with mild-moderate adverse GI
- 25 symptoms reported in the gastric treatment only. However, no significant treatment effects
- were observed for any subjective measures of appetite or meal palatability.
- 27 **Conclusion:** Both gastric and duodenal delivery of Amarasate[®] modulate the release of
- hormones involved in appetite and glycaemic regulation, providing a potential "bitter brake"
- on energy intake in healthy-weight men.

- 31 **Keywords:** hops, *Humulus lupulus*, appetite, satiety, homeostatic regulation, energy intake,
- 32 ghrelin, cholecystokinin, glucagon-like peptide-1, peptide YY, pancreatic polypeptide, blood
- 33 glucose, insulin, glucose-dependent insulinotropic peptide.

INTRODUCTION

34

65

35 Control of energy intake (EI) is central to the success of interventions designed to manage body weight (1) and the consequences of obesity (2-6). The gastrointestinal (GI) tract 36 37 expresses an array of chemosensory receptors and transporters that provide critical inputs into the acute regulation of energy intake, detecting and relaying to the brain the location, 38 chemical composition and concentration of nutritive and non-nutritive compounds in the gut 39 (7, 8). Obesity and poor weight loss outcomes are associated with impaired gut-brain axis 40 signalling (9-13) which may contribute to overeating and poor adherence to dietary restriction 41 42 (14-17). Approaches that restore or enhance gut-brain axis signalling may address this underlying feedback dysregulation. Indeed, enhancement of gut-brain axis signalling may 43 explain many of the benefits of gastric bypass surgery (18), dietary strategies (e.g. high 44 fibre/protein) and pharmaceutical interventions (19, 20) on the control of EI. Importantly, GI 45 chemosensory mechanisms are readily accessible to dietary manipulation and represent an 46 unexploited source of weight management targets (21-23). 47 Bitter taste receptors (T2R) comprise a family of 25 G protein-coupled receptors that are 48 49 expressed in multiple tissues, including enteroendocrine cells (EEC) of the GI tract (24-26) and are thought to have evolved a chemosensory role in the detection of potential harmful 50 51 substances, limiting their ingestion and absorption (27, 28). In vitro, T2R agonists stimulate 52 the release of peptide hormones, such as ghrelin, cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), from gut enteroendocrine cells (29-32). These gut peptide hormones play 53 a key role the homeostatic regulation of appetite, energy intake, gut function, hedonic food 54 perceptions and nutient metabolism (33-37). A number of clinical studies using either 55 encapsulation or intragastric and intraduodenal infusion of bitter tastents have demonstrated 56 effects ranging from increased gut peptide secretion, reduced energy intake or rate of gastric 57 emptying, modifications in subjective ratings of hunger and fullness, and altered glycemic 58 regulation (38-43), although these anorexigeneic effects are inconsistent (43-46), 59 necessitating further investigation of this response. 60 Hops (Humulus lupulus L.) contain a range of bitter compounds including α -acids (humulone, 61 adhumulone and cohumulone) and β-acids (lupulone, adlupulone and colupulone) that are 62 known ligands for human bitter taste receptors (47). They have a long history of use as food 63 additives and bittering agents in brewing, as well as in traditional medicine [40, 41] and have 64 been shown in vitro to stimulate Ca²⁺-dependent CCK release from EEC cells (32).

Administration of hop-derived extracts has also been shown to reduce body weight, fat mass 66 and improve glucose homeostasis in both rodent (48-55) and human studies (39, 50, 56). In 67 addition, our laboratory has demonstrated that administration of a supercritical CO₂ hop 68 extract can reduce subjective ratings of hunger during water-only fasting (57). 69 Here we investigate the efficacy and GI site of action of Amarasate[®], a bitter supercritical 70 CO₂ extract of hops, to modify acute energy intake, hormonal and glycaemic responses, and 71 subjective ratings of appetite, gastrointestinal discomfort, meal palatability and mood in 72 healthy-weight men. 73 **METHODS** 74 **Participants** 75 Healthy-weight men (18–55 years old), with a BMI between 20 and 25 kg/m² were recruited 76 by advertisement in the Auckland region, New Zealand. A telephone pre-screening interview 77 to determine eligibility of interested individuals was followed by a screening visit to verify 78 eligibility by measurement of height and weight, assessment of oral bitter taste sensitivity to 79 80 the hops extract, and determination of health status by self-report and blood tests (HbA1c, liver function, full blood count, iron status). 81 82 Participants were excluded if they had a diagnosed medical condition or were on medications known to affect taste, appetite-related parameters, metabolism or gastrointestinal function. 83 Exclusions also applied to participants currently on a weight-loss programme or taking 84 weight-loss medication or who had significant weight loss or gain (>5 kg) within the last six 85 months, were smokers, or had a history of alcohol or drug abuse. Participants with 86 hypersensitivities or allergies to any foods or ingredients included in the study, as well as 87 those that disliked or were unwilling to consume items listed as study foods or were 88 unwilling or unable to comply with the study protocol, or who were participating in another 89 clinical intervention trial, were also excluded. 90 91 All participants provided informed consent prior to clinical trial enrolment. Human ethics 92 approval was obtained from the Northern B Health and Disability Ethics committee (ref. 93 14/NTB/25) and the trial registered at the Australian and New Zealand clinical trials registry (ref. ACTRN12614000434695). The study was conducted at the Consumer and Products 94

Insights facility of The New Zealand Institute for Plant and Food Research Limited

(Auckland, New Zealand) in March-June 2014.

95

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

Study design A randomized, double-blind, placebo-controlled, 3-treatment crossover study design was used to determine the efficacy and GI site of action of Amarasate® to modify acute energy intake, appetite and postprandial hormonal responses in healthy-weight men. The three treatment arms (Supplemental Table 1) were: Amarasate[®] (500 mg) targeted for release into the stomach (gastric), Amarasate[®] (500 mg) targeted for release in the proximal small intestine (duodenum), and a vehicle control (placebo). Randomisation was conducted using a 3x3 Latin square balanced for treatment order and carryover effects (58, 59). Three one-day visits were required with a washout period of at least one week between visits. The daily protocol is shown in **Figure 1**. Food intake and subjective measures of appetite, gastrointestinal discomfort, vitality, meal palatability and mood were assessed during fully supervised study days using standard methodology as per the recommendations of Blundell et al. (60). **Treatments** To maintain treatment blinding, all treatments contained two sets of opaque capsules, one set administered at 1100 h were delayed release capsules (DRCapsTM, size 0, Capsugel, NJ, USA) designed to release their contents approximately 50–70 min after ingestion, increasing the likelihood of delivery to the duodenum (61). The second set given at 1130 h were standard hydroxypropyl-methylcellulose capsules (VcapsTM, size 0, Capsugel) designed to release in the stomach. The timing of capsule administration was chosen so that the treatment capsules would probably have released their contents in the stomach or duodenum before the ad libitum lunch (1200 h). The three treatment groups were as follows: **Placebo** – two vehicle control delayed-release capsules (1100 h) followed by two vehicle control standard-release capsules (1130 h); Gastric – two vehicle control delayed-release capsules (1100 h) followed by two Amarasate® standard-release capsules (1130 h); **Duodenum** – two Amarasate[®] delayed-release capsules (1100 h) followed by two vehicle control standard-release capsules (1130 h). Each Amarasate® treatment comprised two capsules, each containing 250 mg of a commercially available food-safe supercritical CO₂ extract of hop cones (Humulus lupulus L. 'Pacific Gem') sourced from New Zealand Hops Ltd, NZ, mixed with 125 mg of canola oil as an excipient (a 2:1 hops:oil ratio). The vehicle control capsules utilised in the placebo treatment and for blinding in the gastric and duodenal treatments contained 125 mg of canola

oil. All capsules were filled in-house using the Capsugel Profiller system (Capsugel, Morristown New Jersey, USA) with a coefficient of variation of 2% for loading accuracy. The α - and β -acid composition of the hop supercritical CO₂ extract comprised 51.5% total α -acids (cohumulone 21.1%, humulone 22.3% and adhumulone 8.2%), and 28.3% total β -acids (colupulone 19.7%, lupulone 6.0% and adlupulone 3.1%) as determined by high performance liquid chromatography (HPLC) (**Supplemental Figure 1**) with reference to the American Brewing Association ICE-3 standard as described in (62). The α - and β -acid composition of the Amarasate[®] formulation has previously been shown to remain stable over the duration of use in the current study (57).

Study visits 1–3

Participants arrived at the study facility by 0730 h on test days in an overnight fasted state (no food or drinks apart from water since 2200 h) having abstained from excessive exercise or alcohol consumption the day before. An indwelling venous cannula was inserted into a forearm vein for repeated blood collection. **Figure 1** shows the study visit protocol including timing of meals, treatment administration, and the collection of blood and behavioural measures. During free time between the meals and questionnaires, participants remained inside the facility but were free to read, watch TV or access the internet on their own devices. Participants were free to leave the facility after completion of the final study questionnaire and removal of the cannula at 1600 h.




Figure 1. Protocol for study visits 1–3. Participants arrived fasted (0730 h), were cannulated and provided with a fixed energy (2 MJ) breakfast (0900 h) that they had to complete. Treatments along with matched placebo capsules targeting the duodenum (D) or gastric (G) compartments were administered at 1100 h (T=0 min) and 1130 h (T= 30 min), respectively. Participants were provided with a*d libitum* lunch (1200 h) and snack (1400 h) outcome meals and directed to eat until comfortably full. Blood samples (B) and VAS ratings (V) of appetite, thirst, vitality and gastrointestinal discomfort related-measures were collected throughout the day. Ratings of meal palatability (P) were assessed using VAS scales immediately after every meal. Mood state (M) were assessed in the morning and afternoon using the Profile of Mood State questionnaire. VAS, visual analogue scale; *Ad lib, Ad libitum*.

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

Fixed energy breakfast, ad libitum meals, and EI The fixed energy (2 MJ) breakfast (Supplemental Table 2) consisted of puffed rice cereal with low fat milk and white bread with margarine and jam. Participants were instructed to consume the entire breakfast within 15 min (verified by visual inspection). The outcome ad *libitum* lunch (1200 h, T= 60 min) was a savoury buffet restricted to a beef and tomato pasta sauce and boiled pasta spirals with water (250 mL). Ham sandwiches, cut into quarters with the crusts removed, were provided for the outcome afternoon snack (1400 h, T= 180 min) with water (250 mL). Both ad libitum meals were provided in excess, with participants instructed that they had 30 minutes to eat until they were comfortably full. To minimise distractions, all meals were provided in individual booths with participants instructed not to talk, read or use mobile phones or electronic devices and to remain in the booth for the designated time. Meals were weighed by two separate observers before and after consumption and energy, fat, carbohydrate, and protein intake were calculated with the use of the dietary software program FoodWorks (Professional Edition, version 5; Xyris Software). All meals were designed to have low phytochemical content to minimise non-specific effects on appetite (63). Behavioural measures Visual analogue scales (VAS) were used to assess subjective feelings of hunger, fullness, satiety, and prospective consumption following the methodology outlined in Blundell et al. (60, 64). Additional VAS were used to assess thirst; measures of vitality (energy levels and relaxation); GI discomfort including nausea, urge to vomit, bloating, abdominal discomfort, and heartburn (adapted from (65)); and meal palatability (64) (pleasantness, visual appeal, smell, taste, aftertaste and overall palatability). The VAS questions and anchor statements are provided in **Supplemental Table 3**. Participants marked their responses by placing a vertical line across the 100-mm scale according to subjective feelings, with responses recorded to the nearest mm. Changes in mood states were assessed at 1000 h (T = -60) and 1530 h (T = 270) using the original version of the Profile of Mood States (POMS) questionnaire (66), a 65-item inventory of six subscales: tension-anxiety, depression-dejection, anger-hostility, vigouractivity, fatigue-inertia, and confusion-bewilderment. Participants rated "How are you feeling right now" for each mood descriptor on a 5-point scale anchored by 1 = "not at all" and 5 = "extremely". The total mood disturbance score was computed by adding the five negative

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

subscale scores (tension, depression, anger, fatigue, confusion) and subtracting the vigour score. The occurance of adverse symptoms/events were recorded for each study visit with participants describing symptoms and their severity using a three-point scale of mild, moderate or severe. Participants were also asked to recall any delayed symptoms/events during the washout period at their next visit. **Blood** measurements Blood for peptide hormones analysis was collected into pre-chilled 5-mL EDTA tubes (BD Vacutainer[®], USA) containing a dipeptidyl-aminopeptidase IV inhibitor (25 µL of a 2 mM solution of Diprotin A, Peptides International, Osaka, Japan) and a general protease inhibitor cocktail (Complete Mini EDTA-free protease inhibitor, Roche, Basel, Switzerland) (182 µL of solution made up of one tablet in 2 mL of water). Blood for plasma glucose analysis was collected into sodium fluoride/potassium oxalate Vacutainer® tubes (BD, USA). Upon collection samples were immediately centrifuged (1500xg for 10 min at 4°C) and the plasma snap frozen on dry ice before storage at -80°C until analysis. Ghrelin (active), GLP-1 (active), PYY (total), insulin, GIP (total) and pancreatic polypeptide (PP) concentrations were measured using a multiplexed magnetic bead assay (HMHMAG-34K; Merck-Millipore, Massachusetts USA). Samples were assayed in duplicate and plates read using a MagpixTM system (Luminex, USA) with concentrations determined using a 5parameter curve fit in Analyst 5.1 (Miliplex, USA). Plasma CCK concentrations were determined in duplicate by radioimmunoassay (EURIA-CCK, Eurodiagnostica, Sweden) as per the manufacturer's instructions, with CCK standards formulated in pooled charcoal stripped human plasma. Assay QC data are given in Supplementary Table 4. Plasma glucose was analysed by Lab Services (North Shore Hospital Lab Services, Auckland) using the hexokinase method on a Dimension® Vista 1500 (Siemens AG, Erlangen, Germany). Statistical Analysis A completers only analysis was used to address missing data. Time profile data including VAS ratings and blood biomarkers were analysed with the use of a linear mixed model (SAS software, PROC GLIMMIX function, version 9.4; SAS Institute Inc.) with treatment, sample number, visit number and and treatment order (one of six possible treatment sequences allocated to each subject) and their respective interactions included as fixed effects. Fisher's protected LSD was used to account for multiple testing. Where there was evidence of a main

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

treatment or treatment x time interaction (p < 0.05), F-tests for treatment differences at each time point were conducted using the 'slice' command. Where these were significant (p < 0.05), Fisher's protected LSD post hoc analysis was used for pairwise comparisons between treatments. Area under the curve (AUC) data were calculated from time 0 to 270 min for blood biomarkers, and from 0 to 300 min for VAS measures, and analysed using a linear mixed model (SAS 9.4) with treatment, visit number and and treatment order as fixed effects.. Where there was evidence of a main treatment effect (p < 0.05), Fisher's protected LSD was used to account for multiple testing of pairwise comparisons between treatments. EI data were analysed in the same way, with models fitted separately for the snack, lunch, and total kJ intake measures. For meal palability measures an additional fixed factor of meal (breakfast, lunch and snack) was included in the linear mixed model, while analysis of POMS subscales included the fixed factor of time (pre/post). Results are presented as means \pm SEM; if required, data were log transformed before analysis, with results presented as backtransformed means \pm SEM. Statistical significance was assessed at p <0.05. **Results Participants** Of the 20 healthy-weight male participants randomly assigned into the trial, 19 completed all three arms of the study, with one participant excluded for failure to comply with study protocol (see CONSORT flow diagram, Supplemental Figure 2). Characteristics of the 19 participants included in the final analysis of energy intake and subjective behavioural measures are shown in **Table 1**. A second participant was excluded from blood sample analysis only because of repeated cannula failures and inability to obtain sufficient blood volume. Hence, data on blood biomarkers is presented for 18 participants.

Table 1. Characteristics of the 19 male participants who completed all three treatment arms¹

	Mean ± SD	Range
Age, y	28.9 ± 10.4	18–54
Height, m	1.80 ± 0.08	1.66-1.95
Body weight, kg	76.1 ± 8.3	60.4–94.5
BMI, kg/m ²	23.5 ± 1.4	20.9–25.0
Ethnicity ² :		
New Zealand European	13	
Maori/Pacifica	2	
Asian	3	
Other	1	

¹All measurements were recorded at the screening visit. ²Ethnicity was assessed by self-report.

EI at ad libitum meals

The effects of treatment on EI at the outcome *ad libitum* lunch and snack meals are shown in **Figure 2**. Total EI from the two outcome meals showed a highly significant effect of treatment ($F_{2,34} = 6.0$, p = 0.006), with both the gastric (4320 ± 350 kJ, p = 0.015) and duodenal (4287 ± 350 kJ, p = 0.012) treatments resulting in significant reductions compared with the placebo (5231 ± 350 kJ). A significant effect of treatment ($F_{2,34} = 4.0$, p = 0.027) was observed at the *ad libitum* snack with a reduction of EI in the duodenal treatment (1423 ± 199 kJ, p = 0.044) compared with the placebo (2018 ± 199 kJ), while the values in the gastric treatment (1452 ± 199 kJ, p = 0.056) just failed to reach statistical significance. EI at the *ad libitum* lunch showed no significant effect of treatment.




Figure 2. The effect of treatment on *ad libitum* energy intake (kJ) at the outcome lunch (1200 h), snack (1400 h) and the combined intake (Total intake). Treatments comprised either a vehicle control (Placebo) or a formulated hops extract (Amarasate®) designed to release in the stomach (Gastric) or in the proximal small intestine (Duodenum). Analysis was conducted using the Mixed procedure (SAS 9.4) with treatment, visit number and treatment order as factors. A significant effect of treatment was observed for both the snack ($F_{2.34} = 4.0$, p = 0.027) and for total intake ($F_{2.34}$ = 6.0, p = 0.006). Fisher's LSD post hoc pairwise analysis demonstrated a significant (p = 0.044) reduction in energy intake for the duodenal treatment compared with the placebo at the snack and for both the gastric (p = 0.015) and duodenal (p = 0.012) treatments compared with the placebo when assessed as total intake. Values are means \pm sem, (n = 19). * p < 0.05.

Blood parameters

261

262

263

264 265

266 267

268 269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

Ghrelin, CCK, GLP-1 and PYY

The effects of treatment on plasma concentrations and AUC_{0-270 min} responses of the appetite regulating hormones ghrelin, CCK, PYY and PP are shown in Figure 3A–D. All four peptide hormone profiles exhibited predictable changes driven primarily by the timing of meals. Ghrelin: Plasma concentrations of the orexigenic hormone ghrelin exhibited a significant treatment x time interaction ($F_{30.440} = 1.74$, p = 0.010). Subsequent post hoc analysis demonstrated a significant increase in ghrelin in both gastric (p = 0.0009) and duodenal (p =0.004) treatments compared with the placebo, immediately prior to the ad libitum lunch (T = 60). No significant differences were detected between any of the treatments at any post-lunch time point or for the AUC_{0-270 min} response (**Figure 3A**). *CCK*: A significant main effect of treatment ($F_{2.70} = 5.8$, p < 0.005) and treatment x time $(F_{30,481} = 1.9, p = 0.004)$ interaction were observed for plasma concentrations of the anorexigenic hormone CCK, with a similar pattern of enhanced postprandial CCK secretion observed in both the gastric and duodenal treatments compared with the placebo (Figure 3B). Post hoc analysis demonstrated that plasma CCK concentrations were significantly increased

(p < 0.05) in both Amarasate[®] treatments compared with the placebo at T = 90, 150, 180,

- 290 210, and 240 min. Significant increases (p < 0.05) were also seen at T = 105 and 120 min in
- the gastric and at T = 135 and 270 min in the duodenal treatments compared with the
- 292 placebo. A significant difference between the gastric and duodenal treatments was observed
- 293 at the 90-min time point only (p = 0.024).
- A significant effect of treatment was also seen for the CCK $AUC_{0-270 \text{ min}}$ responses ($F_{2,32} =$
- 8.66, p = 0.001), with increased hormone secretion observed in both the duodenal (p = 0.002)
- and gastric (p < 0.001) treatments compared with the placebo (**Figure 3B**). Gastric and
- 297 duodenal treatments did not differ significantly from each other.
- 298 *GLP-1*: Plasma concentrations of the insulin secretagogue and anorexigenic hormone GLP-1
- 299 exhibited considerable inter-individual variability (including one individual who exhibited
- approximately forty times average baseline levels), though a significant treatment x time
- interaction ($F_{30,422} = 1.5$, p = 0.038) was observed. *Post hoc* analysis demonstrated an
- enhanced (p < 0.05) postprandial response to the *ad libitum* lunch in the gastric treatment at T
- = 90, 105 and 150 min compared with the placebo (**Figure 3C**). The duodenal treatment
- elicited a similarly enhanced postprandial response, with significant (p < 0.05) increases at T
- = 105, 210 and 240 min compared with the placebo. Gastric and duodenal treatments did not
- 306 differ significantly from each other at any time point. No evidence for a main effect of
- treatment was seen for GLP-1 AUC_{0-270 min} responses (**Figure 3C**).
- 308 PYY: A significant effect of treatment ($F_{2,35} = 7.6$, p = 0.002) and a treatment x time ($F_{30,475} =$
- 1.5, p = 0.042) interaction were observed for plasma concentrations of the anorexigenic gut
- 310 hormone PYY (**Figure 3D**). Though considerable inter-individual variability was observed in
- baseline concentrations (two participants were ~10 fold higher than average). *Post hoc*
- analysis demonstrated that when compared with the placebo, gastric delivery of Amarasate[®]
- produced significant increases in PYY immediately prior to the lunch (T= 60), with
- differences becoming more apparent post lunch through to the end of the session (T = 90-270
- min, p < 0.05). The PYY response to the duodenal treatment was significantly elevated
- relative to the response in the placebo treatment only after the ad libitum snack at T=210 and
- 240 (p < 0.05) minutes. A significant difference between gastric and duodenal treatments was
- also observed at T = -120, 135 and 150 min (p < 0.05).
- A significant effect of treatment was seen for the PYY AUC_{0-270 min} responses ($F_{2,32} = 11.14$, p
- 320 < 0.001), with significantly increased PYY secretion observed in the gastric compared with</p>
- both the duodenal (p = 0.027) and placebo (p < 0.0001) treatments. PYY release was also

significantly (p = 0.023) greater in the duodenal treatment than in the placebo (**Figure 3D**)




Figure 3 Plasma concentrations of (A) ghrelin (active); (B) cholecystokinin (CCK); (C) glucagon like peptide-1 (active) (GLP-1) and (D) peptide YY (PYY) following administration of a control (Placebo) or Amarasate® targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively. Arrows indicate capsule administration; grey bars indicate the time allowed for the 2 MJ fixed energy breakfast and the *ad libitum* lunch and snack. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, time, visit number and treatment order as factors. Significant effects of treatment (B and D, p < 0.005) and a treatment x time interaction (A and C, p < 0.04) were observed. Fisher's LSD *post hoc* pairwise comparisons: gastric v placebo (*p < 0.05, ** p < 0.01, *** p < 0.001); duodenal v placebo (^p < 0.05, ^^ p < 0.01, ^^^ p < 0.001); gastric v duodenal (*p < 0.05, ** p < 0.01, *** p < 0.01, **** p < 0.001). Histograms show effect of treatment on AUC_{0-270 min} for each hormone from 0 to 270 min. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number and treatment order as factors. A significant effect of treatment was observed for B and D (p = 0.001) only, with letters denoting significantly (p < 0.05) different means. Values are means ± SEM; n = 18. *Ad lib, ad libitum*.

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

Glucose, Insulin, GIP and PP Effects of treatment on plasma concentrations and AUC_{0-270 min} responses of glucose, insulin, GIP and PP are shown are shown in **Figure 4A–D**. Glucose: Changes in glucose with time (**Figure 4A**) suggest that Amarasate[®] treatment modified postprandial hyperglycemia following the ad libitum lunch (T = 90) only. However, no significant main effect of treatment or treatment x time interaction was observed for blood glucose concentrations or in the glucose AUC_{0-270 min} response. *Insulin:* Plasma insulin concentrations exhibited a significant effect of treatment ($F_{2,39} = 8.6$, p < 0.001) and a treatment x time (F_{30.332} = 1.8, p = 0.011) interaction (**Figure 4B**). Post hoc analysis demonstrated that insulin responses to the ad libitum lunch and snack showed a significant reduction (p < 0.05) following the gastric and duodenal treatments at T= 90, 105, 120, 180 and 210 min compared with the placebo. This difference extended out to T = 240min for the gastric treatement only. Insulin responses in the gastric and duodenal treatments did not differ significantly from each other at any time point. A highly significant effect of treatment ($F_{2.32} = 10.8$, p = 0.0003) was also observed in insulin AUC_{0-270 min} responses (**Figure 4B**), with a reduction in postprandial insulin secretion following the gastric (p = 0.0013) and duodenal (p = 0.0001) treatments compared with the placebo. Insulin AUC₀₋₂₇₀ min responses in the gastric and duodenal treatments did not differ significantly from each other. GIP: Plasma concentrations of the insulin secretagogue GIP exhibited a significant effect of treatment ($F_{2.65} = 6.8$, p < 0.002) and a treatment x time ($F_{30.517} = 1.7$, p = 0.010) interaction. Post hoc analysis demonstrated that the postprandial response to the ad libitum lunch and snack were significantly reduced in both the gastric and duodenal treatments compared with the placebo from T = 90 to 240 min (p < 0.050). Gastric and duodenal treatments did not differ significantly from each other at any timepoint. GIP AUC_{0-270 min} responses (**Figure 4C**) exhibited a highly significant effect of treatment ($F_{2,32} = 15.5$, p <0.0001), with reductions in postprandial GIP secretion following the gastric (p < 0.0001) and duodenal (p < 0.0001) treatments compared with the placebo. Gastric and duodenal treatments did not differ significantly from each other. PP: Plasma concentrations of the pancreatic hormone PP exhibited a significant effect of treatment ($F_{2,69} = 8.8, p = 0.0004$) and a treatment x time interaction ($F_{30,491} = 1.91, p =$ 0.003), increasing following meals in all treatment groups (Figure 4D). Post hoc analysis

demonstrated that postprandial PP responses were significantly (p < 0.05) reduced in both the gastric (T = 90–240 min) and duodenal (T = 105–210 min) treatments compared with the placebo. Duodenal and gastric treatments did not differ significantly from each other at any timepoint. A highly significant effect of treatment ($F_{2,32} = 11.6$, p = 0.0002) was seen for the PP AUC_{0-270 min} responses, with reduced hormone secretion observed in both the duodenal (p = 0.0096) and gastric (p < 0.0001) treatments compared with the placebo (**Figure 4D**). Gastric and duodenal treatments did not differ significantly from each other.





Figure 4. Plasma concentrations of (A) glucose; (B) insulin; (C) glucose-dependent insulinotropic polypeptide (GIP); and (D) pancreatic polypeptide (PP) following administration of a control (Placebo) or Amarasate® targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively. Arrows indicate capsule administration; grey bars indicate the time allowed for the 2 MJ fixed energy breakfast and the *ad libitum* lunch and snack. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, time, visit number and treatment order as factors. A significant effect of treatment (B–D, p < 0.003) was observed. Fisher's LSD *post hoc* pairwise comparisons: gastric v placebo (*p < 0.05, ** p < 0.01, *** p < 0.001); duodenal v placebo (^p < 0.05, ^^ p < 0.01, ^^ p < 0.001); gastric v duodenal (*p < 0.05, ** p < 0.01, *** p < 0.001). Histograms show effect of treatment on AUC0-270 min for each hormone from 0 to 270 min. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number and treatment order as factors. A significant effect of treatment was observed for B–D (p < 0.001) only, with letters denoting significantly (p < 0.05) different means. Values are means ± SEM; n = 18. *Ad lib, ad libitum*.

VAS – appetite

Effects of treatment on the subjective ratings of hunger, fullness, prospective consumption, satiety and thirst over time and as $AUC_{0-300\,\text{min}}$ are shown in **Figure 5A–E**. A predictable pattern driven by meal timing was seen in all VAS profiles. However, there was no evidence for a significant main effect of treatment or treatment x time interaction for any of the changes in VAS appetite profiles or in $AUC_{0-300\,\text{min}}$.



400 Figure 5 VAS ratings of (A) hunger; (B) fullness; (C) prospective consumption; (D) satiety; and (E) thirst 401 following administration of a control (Placebo) or Amarasate® targeted to either the small intestine 402 (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively. Arrows 403 indicate capsule administration; grey bars indicate the time allowed for the 2 MJ fixed energy breakfast 404 and the ad libitum lunch and snack. Analysis was conducted using the mixed procedure (SAS 9.4) with 405 treatment, time, visit number and treatment order as factors. No main effect of treatment or a treatment 406 x time interaction was observed for any measure. Histograms show mean AUC_{0-300 min} for each VAS 407 measure from 0 to 300 min. Analysis was conducted using the mixed procedure (SAS 9.4) with 408 treatment, visit number and treatment order as factors. No significant effects of treatment were seen. 409 Values are means \pm SEM; n = 19. Ad lib, ad libitum. *VAS* – *vitality* 410 Effects of treatment on subjective ratings of energy and relaxation are shown in 411 **Supplemental Figure 3A–B.** Ratings of energy exhibited a significant treatment effect (F_{2.98} 412 = 3.29, p = 0.041), with post hoc analysis demonstrating significantly (p < 0.050) lower 413 energy ratings in the duodenal treatment at T = 120, 135, 150 and 270 min, and in the gastric 414 treatment at T = 150 and 270 min, compared with the placebo. A signicant treatment effect 415 $(F_{2,32} = 4.65, p = 0.017)$ was also seen for AUC_{0-300 min} responses, with lower ratings for the 416 gastric (p = 0.019) and duodenal (p = 0.009) treatments compared with the placebo 417 (Supplemental Figure 3A). Subjective ratings of relaxation were similar throughout the day, 418 419 with no significant main effects of treatment or treatment x time interactions (Supplemental Figure 3B). 420 VAS – Gastrointestinal discomfort 421 Effects of treatment on subjective ratings of nausea, urge to vomit, bloating, abdominal 422 discomfort and heartburn are shown in **Figure 6A–E**. 423 *Nausea:* Ratings of nausea (**Figure 6A**) exhibited a significant treatment effect ($F_{2,124} = 5.5$, p 424 = 0.005), with post hoc analysis demonstrating significantly (p < 0.050) higher nausea ratings 425 in the duodenal treatment at T = -30, 180, 210 and 240 min, and in the gastric treatment at T 426 = 150 and 180 min, compared with the placebo. Significant differences between the gastric 427 and duodenal treatments were seen at T = -30 and 240 min. A significant treatment effect 428 $(F_{2,32} = 10.9, p = 0.0002)$ on AUC_{0-300 min} responses was also observed, with lower ratings in 429 the gastric (p = 0.006) and duodenal (p < 0.0001) treatments than in the placebo. 430 *Urge to vomit:* There was no evidence for a significant main effect treatment or treatment x 431 432 time interactions in the urge to vomit (Figure 6B). However, a significant treatment effect $(F_{2.32} = 3.95, p = 0.029)$ on AUC_{0-300 min} responses was seen, with a small increase in the urge 433

to vomit (p = 0.009) in the duodenal treatment compared with the placebo.

435 *Bloating:* A significant main effect of treatment ($F_{2,127} = 6.83$, p = 0.002) was seen for subjective ratings of abdominal bloating (Figure 6C). Post hoc analysis demonstrated 436 significantly (p < 0.050) higher ratings of abdominal bloating in the duodenal treatment at T 437 = 90-150 and 240 min, and in the gastric treatment at T = 90, 135 and 150 min, than in the 438 placebo (**Figure 6C**). A significant treatment effect ($F_{2,32} = 7.8$, p = 0.002) was also seen on 439 $AUC_{0-300 \text{ min}}$ responses, with a small increase in bloating in the duodenal (p = 0.001) and 440 gastric (p = 0.020) treatments compared with the placebo. 441 Abdominal discomfort: A significant main effect of treatment $(F_{2.116} = 5.65, p = 0.005)$ was 442 seen for ratings of abdominal discomfort (**Figure 6D**), with post hoc analysis demonstrating 443 significantly (p < 0.050) higher abdominal discomfort ratings in the duodenal treatment at T 444 = 15,210 and 240 min, and in the gastric treatment at T = 210 min, than in the placebo. 445 Significant differences between gastric and duodenal treatments were seen at T = 15 min. 446 However, there was no evidence for a significant effect of treatment on AUC_{0-300 min}. 447 448 Heartburn: No significant main effects of treatment or treatment x time interactions were observed for ratings of heartburn or AUC_{0-300 min} response (**Figure 6E**). 449 450




Figure 6 VAS ratings of (A) nausea; (B) urge to vomit; (C) bloating; (D) abdominal discomfort; and (E) heartburn following administration of a control (Placebo) or Amarasate® targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively. Arrows indicate capsule administration; grey bars indicate the time allowed for the 2 MJ fixed energy breakfast and the *ad libitum* lunch and snack. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, time, visit number and treatment order as factors. A significant effect of treatment was observed for A, C and D (p < 0.010). Fisher's LSD *post hoc* pairwise comparisons: gastric v placebo (*p < 0.05, ** p < 0.01, *** p < 0.001); duodenal v placebo (*p < 0.05, ** p < 0.01, *** p < 0.001); gastric v

461 duodenal (*p < 0.05). Histograms show effect of treatment on AUC_{0-300 min} for each VAS scale from 0 to 300 min. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number and 462 463 treatment order as factors. A significant effect of treatment was observed for A–C (p < 0.05), with letters 464 denoting significantly (p < 0.05) different means. Values are means \pm SEM; n = 19. Ad lib, ad libitum. *VAS – Meal palatability* 465 There was no evidence for a main effect of treatment on VAS ratings of pleasantness, visual 466 appeal, smell, taste, aftertaste, or overall palatability for the fixed-energy breakfast or the ad 467 libitum lunch and snack outcome meals (Supplemental Figure 4). 468 Profile of mood states (POMS) 469 470 The effects of treatment on the six mood subscales and total mood disturbance measured prior to treatment administration (Pre) and in the POMS questionnaire are shown in 471 **Supplemental Figure 5A–G.** Only depression-dejection ($F_{2,83} = 3.4$, p = 0.038) and anger-472 hostility ($F_{2,83} = 6.14$, p = 0.003) exhibited a significant main effect of treatment. Post hoc 473 analysis demonstrated a small but significant (p = 0.011) increase (2.3 \pm 1.2) in scoring of 474 depression-dejection following the gastric treatment compared with the placebo (1.5 \pm 1.2) 475 (Supplemental Figure 5B). Small but significant increases in ratings of anger-hostility were 476 also seen following the gastric (2.2 \pm 1.2) treatment compared with the duodenal (1.5 \pm 1.2, 477 p = 0.016) and placebo (1.4 ± 1.2, p = 0.004) treatments (Supplemental Figure 5C). 478 However, these small changes in mood state may be a reflection of social and environmental 479 interactions e.g. self-entertainment activities such as watching TV, reading and socialising. 480 481 Adverse symptoms The numbers of participants reporting adverse symptoms such as loose stool/diarrhea, nausea, 482 rumbling or upset stomach, bloating and headache during the study day, and their subjective 483 ratings of severity (mild, moderate or severe) are shown in Table 2. The primary analysis of 484 485 all 19 participants revealed a total of 14 adverse symptoms, the majority of which (93%) occurred while on the gastric treatment. No adverse symptoms were reported while on the 486 placebo treatment and only one individual reported a reduced frequency of defecation in the 487 week following the duodenal treatment (washout period), which may not have been 488 attributable to the treatment, given the delay. The participant excluded for failure to comply 489 with the study protocol experienced moderate-intensity loose stools and nausea in both 490 491 gastric and duodenal treatments and was included in a separate analysis (in brackets) of 20 participants for completeness. 492

Table 2. The effects of treatment on numbers of reported adverse symptoms and range of self-reported intensities¹.

	Placebo	Gastric	Duodenal
Nausea	-	2/19 (3/20) ² mod	-(1/20) ² mod
Loose stool/diarrhea	-	6/19 (7/20) ² mild-mod	-(1/20) ² mod
Stomach rumbling	-	1/19 mild	-
Upset stomach	-	1/19 mild	-
Bloating	-	2/19 mod	-
Headache	-	1/19 mild	-
Frequency of defecation	ı -	-	1/19 mod ³

¹ Severity of adverse events was reported using a three-point scale of mild, moderate (mod) or severe over the study visit and washout period for each treatment. Treatments comprised a vehicle control (Placebo) or Amarasate® targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively. ²The participant excluded for failure to comply with the study protocol experienced moderate-intensity loose stools and nausea in both gastric and duodenal treatments and was included in the adverse symptom reporting as a separate analysis (in brackets) with all n=20 participants. ³One participant noted a reduced frequency of defecation over the following week washout period.

Gastrointestinal delivery of a bitter hop extract significantly decreased energy intake and

4. Discussion

increased appetite-suppressing CCK, PYY and GLP-1 plasma concentrations. These changes occurred without significant effects on subjective measures of appetite or the hedonic properties of the test meals. However they were accompanied by small increases in subjective ratings of nausea, bloating, urge to vomit and abdominal discomfort, all of which are expected to decrease EI, and may be confounders. The magnitude of total EI suppression (18%) is significant in the context of weight management applications (67) and compares favourably with results from previous studies in humans (0–22%) that have used either encapsulation, intragastric or intraduodenal delivery of a variety of bitter tastants (38, 40, 42, 43, 46, 68, 69).

The current study supports a mechanism of action involving enhanced and sustained release of the anorexigenic gut hormones CCK, GLP-1 and PYY from intestinal EECs. All three gut peptide hormones play a key role in the homeostatic regulation of energy intake, appetite and GI function (reviewed in (70)) and have previously been shown to respond to T2R ligands (29, 30, 44, 48). Maximum post-prandial increases in CCK following Amarasate® treatments were almost 6-fold that of baseline and in the upper range reported for dietary interventions

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

(0.5–7.9 fold) (71)). Greater variablity between individuals and smaller fold changes were observed for GLP-1 (2.4 fold) and PYY (1.8 fold). A recent meta-analysis of CCK, GLP-1 and PYY infusion studies (71) that proposed that the minimum fold changes required to decrease ad libitum energy intake were 3.6, 4.0 and 3.1-fold, respectively. A significant enhancement of the orexigenic hormone ghrelin response prior to the lunch was also seen for both gastric and duodenal targetting of the hop extract. This is consistent with the duodenum being a source of ghrelin secretion, second only to the stomach (72, 73), although pyloric reflux may also play a role (74). Gavage of T2R agonists has also been shown to stimulate the secretion of ghrelin in mice, resulting in a temporary increase in food intake (75). However, our results contrast with several recent reports of either unchanged or supressed ghrelin following intragastric infusion of T2R agonists (quinine, denatoium benzoate) in humans (41, 76), indicating potential T2R specificity in this response. The mechanism(s) by which T2R agonists stimulate ghrelin secretion are poorly understood, as gastric ghrelin-secreting cells are of the closed type and do not directly contact the GI lumen. It is also noteworthy that there was no significant treatment-induced difference in VAS measurements relating to appetite despite the significant decrease in energy intake seen with both hop treatments. Although correlations between subjective assessments (e.g. hunger) and behavioural effects (e.g. energy intake) are often observed, they assess fundamentally different things, have been reported to show weak correlations, and do not always concur (77, 78). Previous studies using either gastric or duodenal delivery of T2R agonists have shown effects on subjective measures of appetite in both men (79-81), and women (41, 82), although many studies show no response (43-46). Interestingly, participants in the current study did achieve similar feelings of fullness at the ad libitum test meals after consuming less food when taking both hop treatments compared with the placebo. Viewed in this context, Amarasate® treatment may modulate early satiety, which is associated with impaired gastric accommadation and gastric emptying (83). Glucoregulatory hormones (e.g. GLP-1, GIP, insulin) and the slowing of gastric emptying are key determinants of postprandial glycemia. Bitter tastants have been shown to stimulate the secretion of the incretin hormone GLP-1 from EEC cell lines (30, 48), while in mice gavage of bitter gourd extract (84) or denatonium benozate (30) stimulates GLP-1 and subsequent insulin secretion, leading to lowering of blood glucose. A recent study in healthy men also demonstrated that intragastric and intraduodenal administration of the bitter tastant quinine similarly lowered plasma glucose, increased plasma insulin and GLP-1, and slowed gastric

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

emptying (40). The current data also demonstrate an enhancement in the postprandial GLP-1 response following gastric and duodenal targeting of hop extract. However, this response was accompanied by a substantial reduction in the postprandial insulin response, with little change in plasma glucose compared with that in the placebo. Interestingly, GIP, the only gut peptide hormone measured that is secreted from the enteroendocrine K-cell subtype, also exhibited a substantial reduction in postprandial response following hop treatments. This is contrast to the observed stimulation of CCK, GLP-1 and PYY producing EECs, suggesting that K-cells lack the appropriate T2Rs. GIP has been shown to be responsible for the majority of the incretin effect in healthy subjects, affecting glycemic levels during the whole postprandial period (85). In contrast, GLP-1 primarily affects glycaemic regulation in the early postprandial phase, delaying gastric emptying and reducing plasma glucagon levels (85). GIP has also recently been demonstrated as a PP secretagogue (85, 86). Hence the suppression of postparndial GIP in the hop treatment groups may in part explain the suppression of insulin and PP observed. GIP secretion is driven primarly by the rate of macronutrient delivery from the stomach to the duodenum (i.e. rate of gastric emptying) (87). Any delay in gastric emptying in the absence of a treatment induced-stimulation would potentially result in this observed decrease (88-90). Although this study did not measure gastric emptying per se, an established action of CCK, GLP-1 and PYY is to delay gastric emptying (91-93). Importantly, regulation of postprandial glycemia was maintained despite reductions in GIP and insulin, indicating a metabolic shift towards greater insulin sensitivity, a possible consequence of increased GLP-1 secretion. Replication of these results using a fixed energy meal would be ideal, as this would remove any influence from the inter-treatment differences in absolute energy intake that occurred at the ad libitum meals. Off-target effects of Amarasate® treatments included small (<10 mm) but significant increases in subjective ratings of nausea, bloating and abdominal discomfort, which are consistent with known effects of CCK, GLP-1 and PYY on upper gastrointestinal sensations (94, 95). The known sedative activity of hop bitter acids may also have contributed to the small decline in subjective ratings of energy following Amarasate[®] treatment (96, 97), although no corresponding effect on relaxation was observed. Virtually all reported adverse symptoms were associated with gastric targeting of the hops extract, with 32% of participants in this treatment reporting an acute bout of mild- to moderate-intensity diarrhea. Targeting delivery to the small intestine improved tolerance of the hop treatment, suggesting that gastric

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

T2Rs may play a key role in detection of ingested toxins, stimulating a host defence mechanism involving net secretion of fluid and electrolytes into the intestinal lumen, accelerating intestinal transit to flush harmful compounds from the GI tract in a process similar to that described for T2Rs in the human and rat large intestine (98). Further optimisation of the dosage of hops extract used and its timing relative to meals may also contribute to a reduction in the side-effect profile. The Amarasate® extract used in the current study is a supercritical CO₂ extract of hop containing a number of hop bitter acids (e.g. cohumulone, humulone, adhumulone, colupulone, lupulone and adlupulone). These α - and β -acids are potent ligands for hT2R-1, 14 and 40, exhibiting reported thresholds of activation as low as 3 nM (47). All three hopresponsive hT2Rs have previously been identified in either the small (31) or large intestine (99, 100). However, little is known regarding the profile of hT2Rs expression in specific EEC cell-types. The functional data from the current study would suggest CCK, GLP-1, PYY and ghrelin-producing EECs express T2R-1, 14 or 40, a T2R expression profile not shared by GIP-producing EECs. It is worth noting that other compounds derived from hops acids have previously been examined as anti-obesity targets, and potential exists for overlapping or synergistic mechanisms of action. Oxidised hop bitter acid extracts have been reported by Morimoto-Kobayashi et al. to reduce fat mass in an overweight population through increased brown adipose tissue thermogenesis (55, 56), with recent work in rats suggesting CCK secretion as a potential mediator of this bioactivity (32). Isomerised α -acids and their derivatives have also shown anti-obesogenic effects, putatively via metabolic regulation (39, 50), although a recent report in mice highlighted a possible role for the T2Rs and anorexigenic hormones (48). Kok et al. (48) showed that the synthetic substituted 1,3-cyclopentadione isomerised alpha acid derivative KDT501 (KinDex Pharmaceuticals) activated T2R1 in vitro and when administered to mice resulted in increased GLP-1, CCK and ghrelin plasma concentrations, and improved glucose and insulin responses. Some limitations of our study should be noted. Targeted delivery of Amarasate[®] to the duodenum may not have occurred in all cases, as the press-fit delayed-release capsules used, can leak (101) or disassemble (102) under gastric conditions in vitro. In addition, the short intervals between the ad libitum lunch, snack and end of daily monitoring may have prevented appropriate treatment differences developing in appetitive VAS measures such as hunger, fullness and prospective consumption (57). The study could also have benefited from

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

the inclusion of measures of gastric emptying. However, GIP secretion is dependent upon nutrient delivery to the duodenum (103) and indirectly supports delayed gastric emptying as a mechanism of action. Another limitation of the study was our inclusion of only healthyweight males as paticipants, done to exclude the potentially confounding effects of the menstrual cycle on energy intake (104) and to ensure robust appetite and glycaemic regulatory mechanisms (9-13). Finally, the effect of repetitive or chronic administration of hop extract on appetite regulation, including possible compensatory mechanisms and effects on weight management, are unknown. Thus, further long-term studies are warranted. In conclusion, both gastric and duodenal delivery of Amarasate[®], a bitter hop extract, suppressed total EI and enhanced pre-meal ghrelin and postprandial CCK, GLP-1 and PYY responses, providing a potential "bitter brake" on energy intake in healthy-weight males. These changes occurred without significant effects on subjective measures of appetite or on any measure of the hedonistic properties of the test meals though small but significant increases were observed in some measures of gastrointestoinal discomfort. Changes in glycaemic regulation were also observed, with reductions in postprandial insulin, PP and GIP responses without a significant effect on the glycaemic response to the *ad libitium* test meals. These data highlight the potential of hop compounds as novel therapeutics to regulate both acute energy intake and glycaemic regulation via modulation of gut peptide release and delayed gastric emptying. Further studies investigating the longer-term effects of lower doses of hop extract as a tool for improved weight management and glycemic regulation should be conducted, to determine potential efficacy.

6. Acknowledgements 639 The authors thank the individuals who kindly agreed to be participants in the clinical trial. 640 We would also like to thank the nurse practitioners who assisted with blood sampling during 641 the clinical trial, Dr Raina Wong for assistance with hormone analysis, Dr Ron Beatson and 642 Dave Anderson for their assistance with hops analysis and selection, and Dr Russell 643 Walmsley for providing medical oversight for this trial. We also thank Prof. Richard 644 Newcomb, Dr Roger Harker and Dr Pramod Gopal for review of the manuscript. This 645 research was funded by the New Zealand Government (NZ Ministry of Business, Innovation 646 & Employment, contract C11X1004). 647 7. Author Contributions 648 Contributor roles (Credit, CASRAI): conceptualization and supervision: JI; funding 649 acquisition: KS, JI; methodology: EW, JI and SP; project administration EW; investigation: 650 EW, KL, MP, HS, CL, KS and JI; data curation: JI; formal analysis MW; visualisation: EW 651 and JI; Writing – original draft: EW, SP and JI; Writing – review & editing: All Authors. 652 8. Conflict of Interest 653 EW, MP, KL, CL, KS, JI are employees of The New Zealand Institute for Plant and Food 654 Research Ltd, a New Zealand Government-owned Crown Research Institute, which has a 655 royalty agreement associated with sales of the Amarasate® extract. The authors declare that 656 there is no individual personal financial relationship and they gain no financial incentive or 657 royalty payment outside of salaries for their employment. SDP and HS declare no conflict of 658 interest related to this product. The sponsors had no role in the design of the study, the 659 collection, analyses, or interpretation of data, in the writing of the manuscript, or in the 660 decision to publish the results. 661

9. References

- 1. Verboven K, Hansen D. Critical Reappraisal of the Role and Importance of Exercise Intervention in the Treatment of Obesity in Adults. Sports Med 2021;51(3):379-89. doi: 10.1007/s40279-020-01392-8.
- Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev 2015;95(3):727-48. doi: 10.1152/physrev.00030.2014.
- Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol 2015;31(2):177-83. doi: 10.1016/j.cjca.2014.11.031.
- Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA. Obesity, Inflammation, and Cancer. Annu
 Rev Pathol 2016;11:421-49. doi: 10.1146/annurev-pathol-012615-044359.
- Himbert C, Delphan M, Scherer D, Bowers LW, Hursting S, Ulrich CM. Signals from the
 Adipose Microenvironment and the Obesity-Cancer Link-A Systematic Review. Cancer Prev
 Res (Phila) 2017;10(9):494-506. doi: 10.1158/1940-6207.CAPR-16-0322.
- 6. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014;10(8):455-65. doi: 10.1038/nrendo.2014.94.
- van der Wielen N, van Avesaat M, de Wit NJW, Vogels JTWE, Troost F, Masclee A, Koopmans
 S-J, van der Meulen J, Boekschoten MV, Müller M, et al. Cross-Species Comparison of Genes
 Related to Nutrient Sensing Mechanisms Expressed along the Intestine. PloS one
 2014;9(9):e107531. doi: 10.1371/journal.pone.0107531.
- 8. Reimann F, Tolhurst G, Gribble FM. G-protein-coupled receptors in intestinal chemosensation. Cell metabolism 2012;15(4):421-31. doi: 10.1016/j.cmet.2011.12.019.
- Benedict C, Axelsson T, Soderberg S, Larsson A, Ingelsson E, Lind L, Schioth HB. Fat mass and obesity-associated gene (FTO) is linked to higher plasma levels of the hunger hormone ghrelin and lower serum levels of the satiety hormone leptin in older adults. Diabetes
 2014;63(11):3955-9. doi: 10.2337/db14-0470.
- Llewellyn CH, Trzaskowski M, van Jaarsveld CM, Plomin R, Wardle J. Satiety mechanisms in genetic risk of obesity. JAMA Pediatrics 2014;168(4):338-44. doi: 10.1001/jamapediatrics.2013.4944.
- Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996;38(6):916-9.
- Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349(10):941-8. doi: 10.1056/NEJMoa030204.
- Lean MEJ, Malkova D. Altered gut and adipose tissue hormones in overweight and obese
 individuals: cause or consequence? International journal of obesity 2016;40(4):622-32. doi:
 10.1038/ijo.2015.220.
- 700 14. Das SK, Gilhooly CH, Golden JK, Pittas AG, Fuss PJ, Dallal GE, McCrory MA, Saltzman E,
 701 Roberts SB. Long Term Effects of Energy-Restricted Diets Differing in Glycemic Load on
 702 Metabolic Adaptation and Body Composition. Open Nutr J 2007;85(4):1023-30.
- 703 15. Del Corral P, Chandler-Laney PC, Casazza K, Gower BA, Hunter GR. Effect of Dietary
 704 Adherence with or without Exercise on Weight Loss: A Mechanistic Approach to a Global
 705 Problem. J Clin Endocrinol Metab 2009;94(5):1602-7. doi: 10.1210/jc.2008-1057.
- 706 16. Redman LM, Heilbronn LK, Martin CK, Alfonso A, Smith SR, Ravussin E. Effect of Calorie 707 Restriction with or without Exercise on Body Composition and Fat Distribution. The Journal 708 of Clinical Endocrinology & Metabolism 2007;92(3):865-72. doi: 10.1210/jc.2006-2184.
- 709 17. Chaput JP, Doucet E, Tremblay A. Obesity: a disease or a biological adaptation? An update.
 710 Obes Rev 2012;13(8):681-91. doi: 10.1111/j.1467-789X.2012.00992.x.
- 18. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lonroth H,
 Fandriks L, Ghatei MA, Bloom SR, et al. Gut hormones as mediators of appetite and weight

- 713 loss after Roux-en-Y gastric bypass. Ann Surg 2007;246(5):780-5. doi: 714 10.1097/SLA.0b013e3180caa3e3.
- 715 19. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M.
 716 Effects of exenatide and lifestyle modification on body weight and glucose tolerance in
 717 obese subjects with and without pre-diabetes. Diabetes care 2010;33(6):1173-5. doi:
 718 10.2337/dc09-1203.
- Skov AR, Toubro S, Ronn B, Holm L, Astrup A. Randomized trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity 1999;23(5):528-36.
- Preen DM, Rasmussen BA, Côté CD, Jackson VM, Lam TKT. Nutrient-Sensing Mechanisms in the Gut as Therapeutic Targets for Diabetes. Diabetes 2013;62(9):3005-13. doi: 10.2337/db13-0523.
- Reimann F, Gribble FM. G protein-coupled receptors as new therapeutic targets for type 2 diabetes. Diabetologia 2016;59:229-33. doi: 10.1007/s00125-015-3825-z.
- 728 23. Janssen S, Depoortere I. Nutrient sensing in the gut: new roads to therapeutics? Trends in
 729 Endocrinology & Metabolism 2013;24(2):92-100. doi:
 730 http://dx.doi.org/10.1016/j.tem.2012.11.006.
- 731 24. Behrens M, Meyerhof W. Oral and extraoral bitter taste receptors. Results Probl Cell Differ 2010;52:87-99. doi: 10.1007/978-3-642-14426-4 8.
- 733 25. Clark AA, Liggett SB, Munger SD. Extraoral bitter taste receptors as mediators of off-target drug effects. FASEB J 2012;26(12):4827-31. doi: 10.1096/fj.12-215087.
- Jaggupilli A, Singh N, Upadhyaya J, Sikarwar AS, Arakawa M, Dakshinamurti S, Bhullar RP, Duan K, Chelikani P. Analysis of the expression of human bitter taste receptors in extraoral tissues. Mol Cell Biochem 2017;426(1-2):137-47. doi: 10.1007/s11010-016-2902-z.
- 738 27. Soranzo N, Bufe B, Sabeti PC, Wilson JF, Weale ME, Marguerie R, Meyerhof W, Goldstein DB.
 739 Positive selection on a high-sensitivity allele of the human bitter-taste receptor TAS2R16.
 740 Curr Biol 2005;15(14):1257-65. doi: 10.1016/j.cub.2005.06.042.
- Sandell MA, Breslin PAS. Variability in a taste-receptor gene determines whether we taste toxins in food. Curr Biol 2006;16(18):R792-R4. doi: DOI 10.1016/j.cub.2006.08.049.
- 743 29. Chen MC, Wu SV, Reeve JR, Jr., Rozengurt E. Bitter stimuli induce Ca2+ signaling and CCK
 744 release in enteroendocrine STC-1 cells: role of L-type voltage-sensitive Ca2+ channels. Am J
 745 Physiol Cell Physiol 2006;291(4):C726-39. doi: 10.1152/ajpcell.00003.2006.
- 746 30. Kim KS, Egan JM, Jang HJ. Denatonium induces secretion of glucagon-like peptide-1 through
 747 activation of bitter taste receptor pathways. Diabetologia 2014;57(10):2117-25. doi:
 748 10.1007/s00125-014-3326-5.
- T49 31. Le Neve B, Foltz M, Daniel H, Gouka R. The steroid glycoside H.g.-12 from Hoodia gordonii
 activates the human bitter receptor TAS2R14 and induces CCK release from HuTu-80 cells.
 Am J Physiol Gastrointest Liver Physiol 2010;299(6):G1368-75. doi:
 10.1152/ajpgi.00135.2010.
- 753 32. Yamazaki T, Morimoto-Kobayashi Y, Koizumi K, Takahashi C, Nakajima S, Kitao S, Taniguchi Y, 754 Katayama M, Ogawa Y. Secretion of a gastrointestinal hormone, cholecystokinin, by hop-755 derived bitter components activates sympathetic nerves in brown adipose tissue. J Nutr 756 Biochem 2018;64:80-7. doi: 10.1016/j.jnutbio.2018.10.009.
- Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R,
 Conen D, Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans.
 Gut 1999;44(1):81-6.
- 760 34. Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin 761 decreases food intake in man. Am J Clin Nutr 1981;34(2):154-60. doi: 10.1093/ajcn/34.2.154.

- Goebel-Stengel M, Stengel A, Wang L, Ohning G, Tache Y, Reeve JR, Jr. CCK-8 and CCK-58
 differ in their effects on nocturnal solid meal pattern in undisturbed rats. Am J Physiol Regul
 Integr Comp Physiol 2012;303(8):R850-60. doi: 10.1152/ajpregu.00365.2011.
- 765 36. Schwartz GJ. The role of gastrointestinal vagal afferents in the control of food intake: current prospects. Nutrition 2000;16(10):866-73.
- 767 37. Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci 2013;7:181. doi: 10.3389/fnins.2013.00181.
- 38. Bitarafan V, Fitzgerald PCE, Little TJ, Meyerhof W, Jones KL, Wu T, Horowitz M, Feinle-Bisset
 C. Intragastric administration of the bitter tastant quinine lowers the glycemic response to a
 nutrient drink without slowing gastric emptying in healthy men. Am J Physiol Regul Integr
 Comp Physiol 2020;318(2):R263-R73. doi: 10.1152/ajpregu.00294.2019.
- 773 39. Obara K, Mizutani M, Hitomi Y, Yajima H, Kondo K. Isohumulones, the bitter component of beer, improve hyperglycemia and decrease body fat in Japanese subjects with prediabetes. Clin Nutr 2009;28(3):278-84. doi: 10.1016/j.clnu.2009.03.012.
- Rose BD, Bitarafan V, Rezaie P, Fitzgerald PCE, Horowitz M, Feinle-Bisset C. Comparative
 Effects of Intragastric and Intraduodenal Administration of Quinine on the Plasma Glucose
 Response to a Mixed-Nutrient Drink in Healthy Men: Relations with Glucoregulatory
 Hormones and Gastric Emptying. J Nutr 2021. doi: 10.1093/jn/nxab020.
- 780 41. Deloose E, Janssen P, Corsetti M, Biesiekierski J, Masuy I, Rotondo A, Van Oudenhove L,
 781 Depoortere I, Tack J. Intragastric infusion of denatonium benzoate attenuates interdigestive
 782 gastric motility and hunger scores in healthy female volunteers. Am J Clin Nutr
 783 2017;105(3):580-8. doi: 10.3945/ajcn.116.138297.
- Iven J, Biesiekierski JR, Zhao D, Deloose E, O'Daly OG, Depoortere I, Tack J, Van Oudenhove L.
 Intragastric quinine administration decreases hedonic eating in healthy women through
 peptide-mediated gut-brain signaling mechanisms. Nutr Neurosci 2019;22(12):850-62. doi:
 10.1080/1028415X.2018.1457841.
- van Avesaat M, Troost FJ, Ripken D, Peters J, Hendriks HF, Masclee AA. Intraduodenal infusion of a combination of tastants decreases food intake in humans. Am J Clin Nutr 2015;102(4):729-35. doi: 10.3945/ajcn.115.113266.
- 44. Bitarafan V, Fitzgerald PCE, Little TJ, Meyerhof W, Wu T, Horowitz M, Feinle-Bisset C. Effects
 of Intraduodenal Infusion of the Bitter Tastant, Quinine, on Antropyloroduodenal Motility,
 Plasma Cholecystokinin, and Energy Intake in Healthy Men. Journal of
 neurogastroenterology and motility 2019;25(3):413-22. doi: 10.5056/jnm19036.
- Little TJ, Gupta N, Case RM, Thompson DG, McLaughlin JT. Sweetness and bitterness taste of
 meals per se does not mediate gastric emptying in humans. Am J Physiol Regul Integr Comp
 Physiol 2009;297(3):R632-9. doi: 10.1152/ajpregu.00090.2009.
- 46. Andreozzi P, Sarnelli G, Pesce M, Zito FP, Alessandro AD, Verlezza V, Palumbo I, Turco F,
 Esposito K, Cuomo R. The Bitter Taste Receptor Agonist Quinine Reduces Calorie Intake and
 Increases the Postprandial Release of Cholecystokinin in Healthy Subjects. Journal of
 neurogastroenterology and motility 2015;21(4):511-9. doi: 10.5056/jnm15028.
- Intelmann D, Batram C, Kuhn C, Haseleu G, Meyerhof W, Hofmann T. Three TAS2R Bitter
 Taste Receptors Mediate the Psychophysical Responses to Bitter Compounds of Hops
 (Humulus lupulus L.) and Beer. Chem Percept 2009;2(3):118-32. doi: 10.1007/s12078-009-9049-1.
- Kok BP, Galmozzi A, Littlejohn NK, Albert V, Godio C, Kim W, Kim SM, Bland JS, Grayson N,
 Fang M, et al. Intestinal bitter taste receptor activation alters hormone secretion and
 imparts metabolic benefits. Mol Metab 2018;16:76-87. doi: 10.1016/j.molmet.2018.07.013.
- 49. Yajima H, Noguchi T, Ikeshima E, Shiraki M, Kanaya T, Tsuboyama-Kasaoka N, Ezaki O,
 810 Oikawa S, Kondo K. Prevention of diet-induced obesity by dietary isomerized hop extract
 811 containing isohumulones, in rodents. International journal of obesity 2005;29(8):991-7. doi:
 812 10.1038/sj.ijo.0802965.

- Yajima H, Ikeshima E, Shiraki M, Kanaya T, Fujiwara D, Odai H, Tsuboyama-Kasaoka N, Ezaki
 O, Oikawa S, Kondo K. Isohumulones, bitter acids derived from hops, activate both
 peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance.
 J Biol Chem 2004;279(32):33456-62. doi: 10.1074/jbc.M403456200.
- Vroegrijk IO, van Diepen JA, van den Berg SA, Romijn JA, Havekes LM, van Dijk KW, Darland G, Konda V, Tripp ML, Bland JS, et al. META060 protects against diet-induced obesity and insulin resistance in a high-fat-diet fed mouse. Nutrition 2013;29(1):276-83. doi: 10.1016/j.nut.2012.05.004.
- Tripp ML, Darland G, Konda VR, Pacioretty LM, Chang JL, Bland JS, Babish JG. Optimized mixture of hops rho iso-alpha acids-rich extract and acacia proanthocyanidins-rich extract reduces insulin resistance in 3T3-L1 adipocytes and improves glucose and insulin control in db/db mice. Nutr Res Pract 2012;6(5):405-13. doi: 10.4162/nrp.2012.6.5.405.
- Sumiyoshi M, Kimura Y. Hop (Humulus lupulus L.) extract inhibits obesity in mice fed a high-fat diet over the long term. Br J Nutr 2013;109(1):162-72. doi: 10.1017/S000711451200061X.
- Everard A, Geurts L, Van Roye M, Delzenne NM, Cani PD. Tetrahydro iso-alpha acids from hops improve glucose homeostasis and reduce body weight gain and metabolic endotoxemia in high-fat diet-fed mice. PloS one 2012;7(3):e33858. doi: 10.1371/journal.pone.0033858.
- 832 55. Morimoto-Kobayashi Y, Ohara K, Takahashi C, Kitao S, Wang G, Taniguchi Y, Katayama M,
 833 Nagai K. Matured Hop Bittering Components Induce Thermogenesis in Brown Adipose Tissue
 834 via Sympathetic Nerve Activity. PloS one 2015;10(6):e0131042. doi:
 835 10.1371/journal.pone.0131042.
- Morimoto-Kobayashi Y, Ohara K, Ashigai H, Kanaya T, Koizumi K, Manabe F, Kaneko Y,
 Taniguchi Y, Katayama M, Kowatari Y, et al. Matured hop extract reduces body fat in healthy
 overweight humans: a randomized, double-blind, placebo-controlled parallel group study.
 Nutr J 2016;15:25. doi: 10.1186/s12937-016-0144-2.
- Walker E, Lo K, Tham S, Pahl M, Lomiwes D, Cooney J, Wohlers M, Gopal P. New Zealand Bitter Hops Extract Reduces Hunger During a 24 h Water Only Fast. Nutrients 2019;11(11). doi: 10.3390/nu11112754.
- Williams EJ. Experimental Designs Balanced for the Estimation of Residual Effects of Treatments. Australian Journal of Chemistry 1949;2(2):149-68. doi: 10.1071/ch9490149.
- 59. John PWM. Statisitcal Design and Analysis of Experiments. New York: Macmillan, 1971.
- 846 60. Blundell J, de Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, Mela D, Salah S, Schuring E, van der Knaap H, et al. Appetite control: methodological aspects of the evaluation of foods.

 848 Obes Rev 2010;11(3):251-70. doi: 10.1111/j.1467-789X.2010.00714.x.
- 849 61. Amo R. DRcaps® Capsules Achieve Delayed Release Properties for Nutritional Ingredients in Human Clinical Study. Capsugel, 2014. no. BAS 420.]
- 62. Committee EBCA. Analytica EBC, European Brewery Convention, Method 7.8. 5th ed. Nürnberg: Verlag Hans Carl Getränke-Fachverlag, 1998.
- Tucci SA. Phytochemicals in the Control of Human Appetite and Body Weight.

 Pharmaceuticals (Basel) 2010;3(3):748-63. doi: 10.3390/ph3030748.
- Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. International journal of obesity 2000;24(1):38-48.
- 858 65. Bovenschen HJ, Janssen MJR, van Oijen MGH, Laheij RJF, van Rossum LGM, Jansen JBMJ.
 859 Evaluation of a gastrointestinal symptoms questionnaire. Digest Dis Sci 2006;51(9):1509-15.
 860 doi: 10.1007/s10620-006-9120-6.
- 861 66. McNair DM, Lorr M, Droppelman LF. Manual for the profile of mood states. San Diego, CA.: Educational and Industrial Testing Service, 1971.

- 863 67. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-864 term weight gain in women and men. N Engl J Med 2011;364(25):2392-404. doi: 865 10.1056/NEJMoa1014296.
- Mennella I, Fogliano V, Ferracane R, Arlorio M, Pattarino F, Vitaglione P. Microencapsulated bitter compounds (from Gentiana lutea) reduce daily energy intakes in humans. Br J Nutr 2016;116:1841-50. doi: 10.1017/s0007114516003858.
- 869 69. Bitarafan V, Fitzgerald PCE, Little TJ, Meyerhof W, Wu T, Horowitz M, Feinle-Bisset C. Effects 870 of Intraduodenal Infusion of the Bitter Tastant, Quinine, on Antropyloroduodenal Motility, 871 Plasma Cholecystokinin, and Energy Intake in Healthy Men. Journal of 872 neurogastroenterology and motility 2019. doi: 10.5056/jnm19036.
- Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N. Ghrelin, CCK, GLP-1,
 and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health,
 Obesity, and After RYGB. Physiol Rev 2017;97(1):411-63. doi: 10.1152/physrev.00031.2014.
- Lim JJ, Poppitt SD. How Satiating Are the 'Satiety' Peptides: A Problem of Pharmacology versus Physiology in the Development of Novel Foods for Regulation of Food Intake.
 Nutrients 2019;11(7). doi: 10.3390/nu11071517.
- Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.
 Endocrinology 2000;141(11):4255-61. doi: 10.1210/endo.141.11.7757.
- Wang HT, Lu QC, Wang Q, Wang RC, Zhang Y, Chen HL, Zhao H, Qian HX. Role of the duodenum in regulation of plasma ghrelin levels and body mass index after subtotal gastrectomy. World J Gastroenterol 2008;14(15):2425-9. doi: 10.3748/wjg.14.2425.
- Muller-Lissner SA, Fimmel CJ, Sonnenberg A, Will N, Muller-Duysing W, Heinzel F, Muller R, Blum AL. Novel approach to quantify duodenogastric reflux in healthy volunteers and in patients with type I gastric ulcer. Gut 1983;24(6):510-8.
- Janssen S, Laermans J, Verhulst PJ, Thijs T, Tack J, Depoortere I. Bitter taste receptors and alpha-gustducin regulate the secretion of ghrelin with functional effects on food intake and gastric emptying. Proc Natl Acad Sci U S A 2011;108(5):2094-9. doi: 10.1073/pnas.1011508108.
- 76. Deloose E, Corsetti M, Van Oudenhove L, Depoortere I, Tack J. Intragastric infusion of the bitter tastant quinine suppresses hormone release and antral motility during the fasting state in healthy female volunteers. Neurogastroenterol Motil 2018;30(1). doi: 10.1111/nmo.13171.
- Sadoul BC, Schuring EA, Mela DJ, Peters HP. The relationship between appetite scores and subsequent energy intake: an analysis based on 23 randomized controlled studies. Appetite 2014;83:153-9. doi: 10.1016/j.appet.2014.08.016.
- 900 78. Poppitt SD, Han S, Strik CM, Kindleysides S, Chan YK. Investigating acute satiation and meal termination effects of a commercial lipid emulsion: A breakfast meal study. Physiology & behavior 2015;152(Pt A):20-5. doi: 10.1016/j.physbeh.2015.09.008.
- 79. Deloose E, Corsetti M, Van Oudenhove L, Depoortere I, Tack JF. In man intragastric
 904 administration of the bitter compound denatonium benzoate decreases hunger and the
 905 occurence of gastric phase III in the fasting state. Gastroenterology 2013;144(5):S548-S. doi:
 906 10.1016/S0016-5085(13)62032-6.
- 907 80. Verschueren S, Janssen P, Andrews CN, Verbeke K, Depoortere I, Tack JF. The Effect of the 908 Bitter Taste Receptor Agonist Denatonium Benzoate on Gastric Emptying, Satiety and Return 909 of Hunger After a Meal in Healthy Volunteers. Gastroenterology 2013;144(5):S548.
- 910 81. Avau B, Rotondo A, Thijs T, Andrews CN, Janssen P, Tack J, Depoortere I. Targeting extra-oral
 911 bitter taste receptors modulates gastrointestinal motility with effects on satiation. Sci Rep
 912 2015;5:15985. doi: 10.1038/srep15985.

- 913 82. Iven J, Biesiekierski JR, Zhao D, Deloose E, O'Daly OG, Depoortere I, Tack J, Van Oudenhove L.
 914 Intragastric quinine administration decreases hedonic eating in healthy women through
 915 peptide-mediated gut-brain signaling mechanisms. Nutr Neurosci 2018:1-13. doi:
 916 10.1080/1028415x.2018.1457841.
- 917 83. Piessevaux H, Tack J, Walrand S, Pauwels S, Geubel A. Intragastric distribution of a 918 standardized meal in health and functional dyspepsia: correlation with specific symptoms. 919 Neurogastroenterol Motil 2003;15(5):447-55. doi: 10.1046/j.1365-2982.2003.00431.x.
- 84. Huang TN, Lu KN, Pai YP, Chin H, Huang CJ. Role of GLP-1 in the Hypoglycemic Effects of Wild
 Bitter Gourd. Evid Based Complement Alternat Med 2013;2013:625892. doi:
 10.1155/2013/625892.
- 923 85. Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S, 924 Stensen S, Lanng AR, Bergmann NC, et al. Separate and Combined Glucometabolic Effects of 925 Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in 926 Healthy Individuals. Diabetes 2019;68(5):906-17. doi: 10.2337/db18-1123.
- 927 86. Veedfald S, Vedtofte L, Skov-Jeppesen K, Deacon CF, Hartmann B, Vilsboll T, Knop FK,
 928 Christensen MB, Holst JJ. Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic
 929 Polypeptide Secretagogue in Humans. J Clin Endocrinol Metab 2020;105(3):e502-e10. doi:
 930 10.1210/clinem/dgz097.
- 931 87. Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, Smout AJ,
 932 Horowitz M, Feinle-Bisset C. Load-dependent effects of duodenal glucose on glycemia,
 933 gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men.
 934 Am J Physiol Endocrinol Metab 2007;293(3):E743-53. doi: 10.1152/ajpendo.00159.2007.
- 935 88. Wilson RM, Boden G, Owen OE. Pancreatic polypeptide responses to a meal and to intraduodenal amino acids and sodium oleate. Endocrinology 1978;102(3):859-63. doi: 10.1210/endo-102-3-859.
- 89. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA,
 89. Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin
 89. Endocrinol Metab 2003;88(8):3989-92. doi: 10.1210/jc.2003-030630.
- 941 90. Krarup T, Holst JJ, Larsen KL. Responses and molecular heterogeneity of IR-GIP after intraduodenal glucose and fat. Am J Physiol 1985;249(2 Pt 1):E195-200. doi: 10.1152/ajpendo.1985.249.2.E195.
- 94. Yamagishi T, Debas HT. Cholecystokinin inhibits gastric emptying by acting on both proximal stomach and pylorus. Am J Physiol 1978;234(4):E375-8. doi: 10.1152/ajpendo.1978.234.4.E375.
- 947 92. Naslund E, Bogefors J, Gryback P, Bjellerup P, Jacobsson H, Holst JJ, Hellstrom PM. GLP-1
 948 inhibits gastric emptying of water but does not influence plasma. Scand J Gastroenterol
 949 2001;36(2):156-62.
- 93. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, Hellstrom PM. GLP-1 slows
 951 solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol
 952 1999;277(3):R910-6. doi: 10.1152/ajpregu.1999.277.3.R910.
- 953 94. Fried M, Feinle C. The role of fat and cholecystokinin in functional dyspepsia. Gut 2002;51 Suppl 1:i54-7. doi: 10.1136/gut.51.suppl 1.i54.
- 95. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and
 956 diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1
 957 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab
 958 2017;19(3):336-47. doi: 10.1111/dom.12824.
- 959
 96. Franco L, Sanchez C, Bravo R, Rodriguez AB, Barriga C, Romero E, Cubero J. The sedative
 960 effect of non-alcoholic beer in healthy female nurses. PloS one 2012;7(7):e37290. doi:
 961 10.1371/journal.pone.0037290.
- 962 97. Zanoli P, Zavatti M. Pharmacognostic and pharmacological profile of Humulus lupulus L. Journal of ethnopharmacology 2008;116(3):383-96. doi: 10.1016/j.jep.2008.01.011.

- 98. Kaji I, Karaki S, Fukami Y, Terasaki M, Kuwahara A. Secretory effects of a luminal bitter tastant and expressions of bitter taste receptors, T2Rs, in the human and rat large intestine. Am J Physiol Gastrointest Liver Physiol 2009;296(5):G971-81. doi: 10.1152/ajpgi.90514.2008.
- 99. Rozengurt N, Wu SV, Chen MC, Huang C, Sternini C, Rozengurt E. Colocalization of the alphasubunit of gustducin with PYY and GLP-1 in L cells of human colon. Am J Physiol Gastrointest Liver Physiol 2006;291(5):G792-802. doi: 10.1152/ajpgi.00074.2006.
- Haraki S-i, Fukami Y, Terasaki M, Kuwahara A. Secretory effects of a luminal bitter
 tastant and expressions of bitter taste receptors, T2Rs, in the human and rat large intestine.
 Am J Physiol Gastrointest Liver Physiol 2009;296(5):G971-81. doi: 10.1152/ajpgi.90514.2008.
- 973 101. Al-Tabakha MM, Arida Al, Fahelelbom KMS, Sadek B, Abu Jarad RA. Performances of New Generation of Delayed Release Capsules. J Young Pharm 2015;7(1):36-44. doi: 10.5530/jyp.2015.1.7.
- 976 102. Miller DS, Parsons AM, Bresland J, Herde P, Pham DM, Tan A, Hsu HY, Prestidge CA, Kuchel T,
 977 Begg R, et al. A simple and inexpensive enteric-coated capsule for delivery of acid-labile
 978 macromolecules to the small intestine. J Zhejiang Univ Sci B 2015;16(7):586-92. doi:
 979 10.1631/jzus.B1400290.
- 980 103. Reimann F, Diakogiannaki E, Moss CE, Gribble FM. Cellular mechanisms governing glucose-981 dependent insulinotropic polypeptide secretion. Peptides 2020;125:170206. doi: 982 10.1016/j.peptides.2019.170206.
- 983 104. Brennan IM, Feltrin KL, Nair NS, Hausken T, Little TJ, Gentilcore D, Wishart JM, Jones KL,
 984 Horowitz M, Feinle-Bisset C. Effects of the phases of the menstrual cycle on gastric
 985 emptying, glycemia, plasma GLP-1 and insulin, and energy intake in healthy lean women. Am
 986 J Physiol Gastrointest Liver Physiol 2009;297(3):G602-10. doi: 10.1152/ajpgi.00051.2009.